EMEA-000576-PIP03-12-M05
Table of contents
Key facts
Invented name |
Xeljanz
|
Active substance |
Tofacitinib
|
Therapeutic area |
Gastroentology-Hepatology
|
Decision number |
P/0009/2021
|
PIP number |
EMEA-000576-PIP03-12-M05
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of ulcerative colitis
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Pfizer Europe MA EEIG
Tel. +44 1304 6466 07 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|